Gradient Denervation Technologies
Gradient Denervation Technologies develops a device-based minimally invasive solution for the treatment of pulmonary hypertension with technology derived from an invention by clinicians from Stanford University. It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund and based in Paris, France.
Sector
Medical Devices
Strategy
MD Start
Status
Live
Website
www.gradientdenervation.com
Related News
Gradient Denervation Technologies appoints Stanton Rowe to Board of Directors and receives FDA approval to expand early feasibility study
Gradient Denervation Technologies enrolls first patient in early feasibility study of pulmonary artery denervation system
Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys
Gradient Denervation Technologies enrolls initial patient in first-in-human study of pulmonary artery denervation technology
Gradient Denervation Technologies announces appointment of Martin Grasse as Chief Executive Officer
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.